Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial

Ronald Levy, MD, Patrick M. Reagan, MD, Jonathan W. Friedberg, MD, Nancy L Bartlett, MD, Leo I. Gordon, MD, Abraham Leung, MD, Joanna Peterkin, MD MS, Biao Xing, Robert Coffman, PhD, Robert Janssen, MD, Albert Candia, PhD, Michael Khodadoust, MD PhD, Matthew J. Frank, MD PhD, Steven R Long, MD, Debra K Czerwinski, Michael Chu, MD

Blood (2016) 128 (22): 2974.

https://doi.org/10.1182/blood.V128.22.2974.2974

Published: 2016

Journal Articles

Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN

Debra K Czerwinski, Steven R Long, MD, Michael Khodadoust, MD PhD, Matthew J. Frank, MD PhD, Michael P. Chu, MD, Ami Okada, PhD, Kathleen A McDonald, BA, Holbrook E Kohrt, MD PhD, Nancy L Bartlett, MD, Patrick M. Reagan, MD, Jonathan W. Friedberg, MD MMSc, Leo I. Gordon, MD, Robert Coffman, PhD, Robert Janssen, MD, Ronald Levy, MD

Blood (2015) 126 (23): 1539.

https://doi.org/10.1182/blood.V126.23.1539.1539

Published: 2015

Journal Articles

Dose Finding in Human Trials of TLR9 Agonists: Induction of Interferon-α Inducible Genes in Blood Mononuclear Cells as a Measure of Biologic Activity of 1018 ISS.

James N. Lowder, MD, Jonathan W. Freidberg, MD, Jennifer Kelly, Arnold S. Freedman, MD, Robert Coffman, PhD, Holger Kanzler, PhD, Paul Sims, Jimmy Hwang, MD, Nicholas Haining

Blood (2007) 110 (11): 3844.

https://doi.org/10.1182/blood.V110.11.3844.3844

Published: 2007

Journal Articles

A Novel Role for CpG Oligonucleotides in Tumor Immunotherapy: CpG-ODN Induce Targeted Chemokine-Induced Lymphocyte Migration to the Peripheral Tissues in Humans.

W. Nicholas Haining, Holger Kanzler, Jeffrey Davies, Linda Drury, Jeffrey Kutok, Thomas Brenn, Jill Angelosanto, John Evans, Kate Russell, Stephen Rivoli, Suzanne George, Thomas Morgan, Xiaochun Li, Robert Coffman, Patrick Wen, George Demetri, Lee Nadler

Blood (2007) 110 (11): 1791.

https://doi.org/10.1182/blood.V110.11.1791.1791

Published: 2007

Journal Articles

Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).

Jonathan W. Friedberg, MD, MMSc, Jennifer Kelly, MPH, Jeffrey L. Kutok, MD, Rabih Salloum, MD, David C. Fisher, MD, Elizabeth Ronan, Virginia Dalton, RN, Lynn Rich, RN, Diana Marquis, Paul G. Rothberg, MD, Jane Liesveld, MD, Richard I. Fisher, MD, Robert Coffman, PhD, Tim Mosmann, PhD, Arnold S. Freedman, MD

Blood (2006) 108 (11): 2713.

https://doi.org/10.1182/blood.V108.11.2713.2713

Published: 2006

Journal Articles

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

Jonathan W. Friedberg, MD, Jennifer Kelly, Jeffrey L. Kutok, MD, Rabih Salloum, MD, Thomas Brenn, MD, David C. Fisher, MD, Elizabeth Ronan, Mary McCauley, RN, Lynn Rich, RN, Diana Marquis, Paul G. Rothberg, PhD, Jane Liesveld, MD, Richard I. Fisher, MD, Robert Coffman, PhD, Tim Mosmann, PhD, Arnold S. Freedman, MD

Blood (2005) 106 (11): 2434.

https://doi.org/10.1182/blood.V106.11.2434.2434

Published: 2005

Journal Articles

Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell–depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists

Antonella Mencacci, Katia Perruccio, Angela Bacci, Elio Cenci, Roberta Benedetti, Massimo F. Martelli, Francesco Bistoni, Robert Coffman, Andrea Velardi, Luigina Romani

Blood (2001) 97 (5): 1483–1490.

https://doi.org/10.1182/blood.V97.5.1483

Published: 2001

NARROW

SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial

Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN

Dose Finding in Human Trials of TLR9 Agonists: Induction of Interferon-α Inducible Genes in Blood Mononuclear Cells as a Measure of Biologic Activity of 1018 ISS.

A Novel Role for CpG Oligonucleotides in Tumor Immunotherapy: CpG-ODN Induce Targeted Chemokine-Induced Lymphocyte Migration to the Peripheral Tissues in Humans.

Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell–depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists

Email alerts

ASH Publications

American Society of Hematology

SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial

Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN

Dose Finding in Human Trials of TLR9 Agonists: Induction of Interferon-α Inducible Genes in Blood Mononuclear Cells as a Measure of Biologic Activity of 1018 ISS.

A Novel Role for CpG Oligonucleotides in Tumor Immunotherapy: CpG-ODN Induce Targeted Chemokine-Induced Lymphocyte Migration to the Peripheral Tissues in Humans.

Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell–depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only